The Blue Buffalo Veterinary Clinical Trials Office (BBVCTO)
The mission of the Blue Buffalo Veterinary Clinical Trials Office (BBVCTO)* is to help animals and people live longer, healthier lives by evaluating effective interventions to prevent and treat illness.
*The clinical trial office name does not indicate support or use of Blue Buffalo products in clinical trials.
Advancing the Health of Animals and Humans
Established in 2007 and housed in the Ohio State University Veterinary Medical Center (VMC), our clinical trials office is one of the largest established and reputable clinical trials offices in the country, providing unmatched services, and overseeing over 30 to 50 clinical trials each year on client-owned animals with naturally occurring diseases. These trials drive the discovery and translation of innovative ideas. Knowledge gained from these trials have resulted in new treatments for cancer (lymphoma), heart disease, kidney disease and more.
The BBVCTO partners with the Ohio State Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, and the Center for Clinical and Translational Sciences to provide a comprehensive approach to improving both animal and human health.
In this section
How do I enroll my pet in a clinical trial?
Learn more about your pets eligibility and the benefits of participation. We are grateful to all of our pet heroes for helping advance science and impacting countless animal and human patients.
Partnering with the Clinical Trials Office
The BBVCTO offers many services to support internal clinical investigators, external sponsors who are interested in partnering on a clinical trial and referring veterinarians who would like to promote clinical trials to owners.
Please sign up to receive updates about our current clinical trials here, and stay tuned to our website if you do not see a current trial that fits you pet. We are always trying to improve the well being of our animals and new studies are being added every month.
Biospecimen Repository
The Biospecimen Repository collects samples from animals affected by a variety of illnesses and stores them for future use by investigators. These samples are incredibly valuable to researchers working to propel ground-breaking advances. The BBVCTO is the only center in the country supported by both the National Institutes of Health (NIH) Clinical Translational Science Award and a National Cancer Institute (NCI) Comprehensive Cancer Center Support Grant.
Hundreds of animal participants are enrolled in BBVCTO clinical trials across the entire Ohio State University Veterinary Health System, which provides care for more than 72,000 canine, feline, equine and farm animal patients each year.
Publications
Veterinary clinical trials are a unique opportunity to contribute to progress in medicine. Knowledge from clinical trials not only improve the lives of your pet and other pets, but also impact countless humans. Here are some highlights of the publications of clinical trials made possible thanks to our Pet Heroes.
- Effect of a struvite dissolution diet in cats with naturally occurring struvite urolithiasis (2020)
- Amino acid status in dogs with protein‐losing nephropathy (2019)
- Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease (2019)
- Comparison of Computed Tomography and Ultrasound Techniques for Quantifying Canine Urinary Bladder Transitional Cell Carcinoma Tumor Volume (2018)
- Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer (2018)
- Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma (2018)
- MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines (2018)
- Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib (2018)
- Consecutive day HSP90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors (2018)
- KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells (2018)
- Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia (2017)
- Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor‐23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease (2017)
- Dogs as a Model for Cancer (2016)
- A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma (2016)
- A simplified method of walking track analysis to assess short-term locomotor recovery after acute spinal cord injury caused by thoracolumbar intervertebral disc extrusion in dogs (2016)
- Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma (2016)
- Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study (2015)
- The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal (2015)
- Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma (2015)